Linda Liau elected to Taiwan’s Academia Sinica

Glen Barber named director of Center for Innate Immunity and Inflammation at Ohio State’s Pelotonia Institute for Immuno-Oncology

Glen Barber was named director of the Center for Innate Immunity and Inflammation within the Pelotonia Institute for Immuno-Oncology at the Ohio State University Comprehensive Cancer Center—James Cancer Hospital and Solove Research Institute.

July 12, 2024

Vol.50 No.28

In Brief

UCLA radiation oncologists awarded $1.8M to advance personalized cancer therapy

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have received a $1.8 million grant from NCI to advance their work in personalizing cancer treatment.

July 12, 2024

Vol.50 No.28

In Brief

Sanaz Memarzadeh receives $4.1M to develop immune therapies for ovarian cancer

Sanaz Memarzadeh of UCLA has received two grants totaling $4.1 million to develop advanced cell-based immune therapies for high-grade serous ovarian cancers that have become resistant to conventional treatments.

July 12, 2024

Vol.50 No.28

Clinical Roundup

Tai Chi reduces risk of inflammatory disease, treats insomnia among breast cancer survivors

Both Tai Chi and cognitive behavioral therapy can reduce insomnia in breast cancer survivors but also may provide additional health benefits by reducing inflammation and bolstering anti-viral defenses, according to a study led by UCLA Health researchers. The work was published in Brain, Behavior, and Immunity.

June 28, 2024

Vol.50 No.26

Clinical Roundup

NLRC5 is an innate immune sensor that plays a crucial role in PANoptotic cell death

NLRC5 plays a previously unknown role as an innate immune sensor, triggering cell death, according to new research from St. Jude Children’s Research Hospital. The findings, published in Cell, show how NLRC5 drives PANoptosis, a prominent type of inflammatory cell death.

June 21, 2024

Vol.50 No.25

Clinical Roundup

AI improves physicians’ ability to identify prostate cancer extent

Investigators from UCLA Health found using artificial intelligence to help map out the boundaries of cancerous prostate tissue can significantly reduce the risk of underestimating the extent of prostate cancer—an advancement that can help ensure an accurate diagnosis, precise treatment planning and effective surgical procedures.

June 14, 2024

Vol.50 No.24

Linda Liau elected to Taiwan’s Academia Sinica

YOU MAY BE INTERESTED IN

Glen Barber named director of Center for Innate Immunity and Inflammation at Ohio State’s Pelotonia Institute for Immuno-Oncology

UCLA radiation oncologists awarded $1.8M to advance personalized cancer therapy

Sanaz Memarzadeh receives $4.1M to develop immune therapies for ovarian cancer

Tai Chi reduces risk of inflammatory disease, treats insomnia among breast cancer survivors

NLRC5 is an innate immune sensor that plays a crucial role in PANoptotic cell death

AI improves physicians’ ability to identify prostate cancer extent

Renew today!

Subscriber content

Login